Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 19, Issue 10, 2004, Pages 2570-2575

  Wanner, Christoph ^a   Bahner, Udo ^b   Mattern, Renate ^a   Lang, Dietmar ^c   Passlick Deetjen, Jutta ^c  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b Kuratorium fur Dialyse/Nierentransp   (Germany)

^c FRESENIUS MEDICAL CARE   (Germany)

Author keywords

Acute phase proteins; Apolipoproteins; High flux haemodialysis; Lipids; Oxidative stress; Polysulphone

Indexed keywords

APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; LOW DENSITY LIPOPROTEIN; POLYSULFONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DIALYSIS MEMBRANE; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIPID ANALYSIS; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; APOLIPOPROTEINS; BIOCOMPATIBLE MATERIALS; BIOLOGICAL MARKERS; CELLULOSE; CHOLESTEROL; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; LIPIDS; LIPOPROTEINS, LDL; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; OXIDATIVE STRESS; POLYMERS; RENAL DIALYSIS; SULFONES; UREMIA;

EID: 5444260494     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh415     Document Type: Article

References (22)

1. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003; 14: 1927-1939
2. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592
3. Josephson MA, Fellner SK, Dasgupta A. Improved lipid profiles in patients undergoing high-flux hemodialysis. Am J Kidney Dis 1992; 20: 361-366
4. Seres DS, Strain GW, Hashim SA et al. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 1993; 3: 1409-1415
5. Blankestijn PJ, Vos PF, Rabelink TJ et al. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995; 5: 1703-1708
6. Goldberg IJ, Kaufman AM, Lavarias VA et al. High-flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease. Nephrol Dial Transplant 1996; 11 [Suppl 2]: 104-107
7. Forster PB, Deppisch R, Fürst P et al. Immunophenotyping and LDL receptor activity analysis in monocytes/macrophages during low- and high-flux haemodialysis. Nephrol Dial Transplant 1999; 14 [Suppl 4]: 49-51
8. Merello Godino JI, Rentero R, Orlandini G, Marcelli D, Ronco C. Results from EuCliD® (European Clinical Dialysis Database): impact of shifting treatment modality. Int J Artif Organs 2002; 25: 1049-1060
9. House AA, Wells GA, Donnelly JG et al. Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 2000; 15: 1029-1034
10. Ottosson P, Attman PO, Knight C et al. Do high-flux dialysis membranes affect renal dyslipidemia? ASAIO J 2001; 47: 229-234
11. Bowry SK, Ronco C. Surface topography and surface elemental composition analysis of Helixone, a new high-flux polysulfone dialysis membrane. Int J Artif Organs 2001; 24: 757-764
12. Daugirdas JT. Second generation logarithmic estimates of variable-volume, single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213
13. Ikonomov V, Haase G, Stefanidis I, Melzer H, Mann H. Filtration fluid for hemodialysis treatment. Int J Artif Organs 2002; 25: 379-385
14. Stein DT, Devaraj S, Balis D et al. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001; 21: 2026-2031
15. Mann CJ, Troussard AA, Yen FT et al. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J Biol Chem 1997; 272: 31 348-31 354
16. Dumler F, Stalla K, Mohini R et al. Clinical experience with short-time hemodialysis. Am J Kidney Dis 1992; 19: 49-56
17. Hirany S, O'Byrne D. Devaraj S et al. Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease. Clin Chem 2000; 46: 667-672
18. Oda H, Yorioka N, Okushin S et al. Remnant-like particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis. Nephron 1997; 76: 7-14
19. Maggi E, Finardi G, Poli M et al. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis 1993; 4: 1119-1122
20. Ziouzenkova O, Asatryan L, Akmal M et al. Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J Biol Chem 1999; 274: 18 916-18 924
21. Cheung AK, Levin NW, Greene T et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO Study. J Am Soc Nephrol 2003; 14: 3251-3263
22. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61: 1887-1893